Ubs Group Ag Cardiol Therapeutics Inc. Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
A detailed history of Ubs Group Ag transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 497,857 shares of CRDL stock, worth $542,664. This represents 0.0% of its overall portfolio holdings.
Number of Shares
497,857
Previous 234,818
112.02%
Holding current value
$542,664
Previous $302,000
59.6%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CRDL
# of Institutions
43Shares Held
6.92MCall Options Held
25.9KPut Options Held
1.7K-
Tejara Capital LTD London, X03.19MShares$3.48 Million1.2% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD857KShares$934,5520.22% of portfolio
-
Pvg Asset Management Corp Golden, CO437KShares$476,7241.99% of portfolio
-
Lion Street Advisors, LLC340KShares$370,6270.15% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9293KShares$319,4310.15% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $67.5M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...